$TPIV up 10% on low volume Posted On: 05/27/20
Post# of 29735
Posted On: 05/27/2014 2:40:34 PM
$TPIV up 10% on low volume
Posted On: 05/27/2014 9:07:26 AM
Avatar
Posted By: fitzkarz
$TPIV @ $1.66
SeeThruEquity Initiates Research Coverage on TapImmune with Target Price of $6.97
New York, NY / ACCESSWIRE / May 27, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on TapImmune, Inc. (OTCQB: TPIV).
“TapImmune’s breast cancer vaccine is applicable to over 50% of the population. The vaccine is not limited to breast cancer, as Her2/neu is a target for the vaccine in both colorectal and ovarian cancer, where there are very few therapeutic options,” commented Ajay Tandon, CEO of SeeThruEquity. “We look forward to following the company’s development as it addresses this market opportunity. We are initiating coverage with a price target of $6.97 per share.”
Additional investment highlights are as follows:
- Unique vaccine platform. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's ("Prime" and "Boost" approach utilizes a proprietary set of peptide antigens to broadly stimulate the cellular immune system.
- TPIV100 breast cancer program greatly expands patient market. TapImmune is currently developing a new HER2/neu breast cancer vaccine technology. The company plans to release data from the phase I trial of this vaccine and commence a phase Ib/II trial in 4Q14E. The current standard of care, Herceptin(r), generated sales of $6bn in 2013. Compared to Herceptin, which can only be used with 15-20% of the HER2/neu breast cancer patient population, TapImmune’s breast cancer vaccine is applicable to over 50% of the population.
- Strong pipeline and numerous milestone announcements expected. TapImmune is focused on developing four product candidates, two of which are currently finishing phase I studies at the Mayo Clinic, Rochester MN.
The report is available here: TPIV Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.
Please review important disclosures on our website at http://www.seethruequity.com/.
About TapImmune, Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.
Please visit the Company’s website at http://www.tapimmune.com/ for details.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit http://www.seethruequity.com/.
Contact:
Ajay Tandon
SeeThruEquity
(646) 495-0939
Source: SeeThruEquity
Source: Accesswire IA (May 27, 2014 - 9:02 AM EDT)
News by QuoteMedia
Read More: http://investorshangout.com/post/view?id=1546...z32wVsq2aN
Posted On: 05/27/2014 9:07:26 AM
Avatar
Posted By: fitzkarz
$TPIV @ $1.66
SeeThruEquity Initiates Research Coverage on TapImmune with Target Price of $6.97
New York, NY / ACCESSWIRE / May 27, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on TapImmune, Inc. (OTCQB: TPIV).
“TapImmune’s breast cancer vaccine is applicable to over 50% of the population. The vaccine is not limited to breast cancer, as Her2/neu is a target for the vaccine in both colorectal and ovarian cancer, where there are very few therapeutic options,” commented Ajay Tandon, CEO of SeeThruEquity. “We look forward to following the company’s development as it addresses this market opportunity. We are initiating coverage with a price target of $6.97 per share.”
Additional investment highlights are as follows:
- Unique vaccine platform. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's ("Prime" and "Boost" approach utilizes a proprietary set of peptide antigens to broadly stimulate the cellular immune system.
- TPIV100 breast cancer program greatly expands patient market. TapImmune is currently developing a new HER2/neu breast cancer vaccine technology. The company plans to release data from the phase I trial of this vaccine and commence a phase Ib/II trial in 4Q14E. The current standard of care, Herceptin(r), generated sales of $6bn in 2013. Compared to Herceptin, which can only be used with 15-20% of the HER2/neu breast cancer patient population, TapImmune’s breast cancer vaccine is applicable to over 50% of the population.
- Strong pipeline and numerous milestone announcements expected. TapImmune is focused on developing four product candidates, two of which are currently finishing phase I studies at the Mayo Clinic, Rochester MN.
The report is available here: TPIV Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.
Please review important disclosures on our website at http://www.seethruequity.com/.
About TapImmune, Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.
Please visit the Company’s website at http://www.tapimmune.com/ for details.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit http://www.seethruequity.com/.
Contact:
Ajay Tandon
SeeThruEquity
(646) 495-0939
Source: SeeThruEquity
Source: Accesswire IA (May 27, 2014 - 9:02 AM EDT)
News by QuoteMedia
Read More: http://investorshangout.com/post/view?id=1546...z32wVsq2aN
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼